Hiroyasu, Sho http://orcid.org/0000-0002-8290-2272
Zeglinski, Matthew R.
Zhao, Hongyan
Pawluk, Megan A. http://orcid.org/0000-0002-8709-5115
Turner, Christopher T. http://orcid.org/0000-0001-7409-4386
Kasprick, Anika
Tateishi, Chiharu
Nishie, Wataru
Burleigh, Angela
Lennox, Peter A.
Van Laeken, Nancy
Carr, Nick J.
Petersen, Frank
Crawford, Richard I.
Shimizu, Hiroshi
Tsuruta, Daisuke
Ludwig, Ralf J. http://orcid.org/0000-0002-1394-1737
Granville, David J. http://orcid.org/0000-0001-6985-2816
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research
Article History
Received: 29 November 2019
Accepted: 7 December 2020
First Online: 12 January 2021
Competing interests
: D.J.G. is a Co-Founder, Chief Scientific Officer, and Consultant of viDA Therapeutics, Inc., which developed VTI-1002, a granzyme B inhibitor used in this manuscript. The remaining authors have no competing interests to declare.